Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Share:
Related TEVA
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
14 Biggest Mid-Day Gainers For Tuesday
Related NVS
This Analyst Predicts Bullish Growth Outlook For Incyte
What Pharmaceuticals Spend On Lobbying To Influence Trump

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Related Articles (TEVA + NVS)

View Comments and Join the Discussion!
Loading...
Loading...